A humanized anti-Trop2 ADC (hRS7) was effective in controlling tumor growth in two human pancreatic cancer xenograft models when given as eight treatments, whereas the treatment with the pro-drug irinotecan (given at a SN-38-dose equivalent) had no significant effect on tumor growth. The gene discussed is TACSTD2; the disease is neoplasm.